Arcellx, CAR T Therapy, CART DDBCMA, chimeric antigen receptor, Farashin Pharma, Multi myeloma
YARJEJAR KUSA DA KITE DA ARCELLX DOMIN HADA KYAUTA DA SAMUN SAMUN KASANCEWAR MATSALAR CLINICAL CART-DDBCMA A CIKIN MYELOMA DA YAWA.
SANTA MONICA, Calif. & REDWOOD CITY, Calif. -- (KASUWA WIRE) - Kite, Kamfanin Gileyad (NASDAQ: GILD), da Arcellx, Inc. (NASDAQ: ACLX), a yau sun sanar da rufe kamfanonin' a baya. ya sanar da dabarun duniya..
bALL, Brexucabtagene autoleucel, Farashin Pharma, Tecartus, ZUMA-3
Brexucabtagene autoleucel an amince da shi ta FDA don sake dawowa ko refractory B-cell precursor m lymphoblastic cutar sankarar bargo.
Oktoba 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) Hukumar Abinci da Magunguna ta amince da ita ga manya marasa lafiya da suka koma ko tantanin halitta B-cell precursor m lymphoblastic leukemia (ALL). A cikin..
axicabtagene ciloleucel, Mota-T Ciwon ƙwayar cuta, CD19, ƙwayar lymphoma, Farashin Pharma, lymphoma follicular refractory, lymphoma follicular da ta sake dawowa, Yascarta
FDA ta ba da izinin axicabtagene ciloleucel wanda aka hanzarta don sake dawowa ko raunin lymphoma follicular follicular.
Agusta 2021: FDA ta ba da axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) amincewa da gaggawa ga manya marasa lafiya tare da relapsed ko refractory follicular lymphoma (FL) bayan biyu ko fiye Lines na tsarin jiyya. A sing..